Clinical Trial Update: A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors [Phase 1]

View source ↗

Summary

This Phase 1 trial assesses Autogene Cevumeran (RO7198457) as a single agent and in combination with atezolizumab across multiple locally advanced or metastatic…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Colorectal Cancer
• Head and Neck Cancer
• Melanoma
• Non-small Cell Lung Cancer
• Renal Cell Carcinoma
• Triple-negative Breast Cancer

Drugs mentioned

• Atezolizumab (atezolizumab)
• Autogene Cevumeran (autogene cevumeran)

Snippet

Sponsor: Genentech, Inc. | Conditions: Melanoma, Non-Small Cell Lung Cancer | Phase 1 | Status: COMPLETED